RESUMEN
Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53-year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.
Asunto(s)
Antiinflamatorios/efectos adversos , Anticuerpos Monoclonales/efectos adversos , Hipergammaglobulinemia/complicaciones , Inmunoglobulina A , Mieloma Múltiple/inducido químicamente , Piodermia Gangrenosa/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Progresión de la Enfermedad , Humanos , Infliximab , Masculino , Persona de Mediana Edad , Mieloma Múltiple/patología , Lesiones Precancerosas/patologíaRESUMEN
Genetic factors are known to be important in the development of Hodgkin lymphoma (HL). Interleukin-10 (IL-10) secretion by both malignant and reactive cells is thought to be important in the pathogenesis of HL especially Epstein-Barr virus (EBV) positive cases. Polymorphisms of the IL-10 gene have been reported to be associated with susceptibility to EBV infection. The cytotoxic response to EBV is determined by a Th1 biased immune response which is characterised by interferon gamma (IFNgamma) secretion. We therefore investigated polymorphisms in the IL-10 (-1082 G/A and -592 C/A) and IFNgamma (intron 1 CA repeat) genes as predisposing factors in the development 147 cases of HL. A difference of borderline statistical significance was demonstrated for the IFNgamma gene polymorphism but significance was lost when analysis was restricted to the common genotypes. No significant differences in the distributions of genotypes were found for the IL-10 gene polymorphisms. IL-10 and IFNgamma levels were also measured on 26 patients with HL. No statistically significant differences were detected when the results were analysed by genotype. We found little evidence IL-10 and IFNgamma genotypes predispose to the development of HL or influence the inflammatory host response.
Asunto(s)
Enfermedad de Hodgkin/genética , Interferón gamma/genética , Interleucina-10/genética , Polimorfismo Genético , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Concanavalina A/metabolismo , Femenino , Genotipo , Haplotipos , Herpesvirus Humano 4/metabolismo , Humanos , Inflamación , Interferón gamma/metabolismo , Interleucina-10/metabolismo , Intrones , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND AND OBJECTIVES: Routine irradiation of cellular blood products is not presently recommended for patients with non-Hodgkin's lymphoma (NHL). MATERIALS AND METHODS: We report the case of a 72-year-old-man with Waldenstrom's macroglobulinaemia who developed transfusion-associated graft-versus-host disease (TA-GvHD) 13 days following a non-irradiated red cell transfusion. RESULTS: The patient had not previously received purine analogues and none of the donors was homozygous for a human leucocyte antigen (HLA) haplotype that was shared by the recipient. Therefore, his only apparent risk factor was lymphoplasmacytoid NHL. CONCLUSIONS: This case further strengthens the argument that NHL per se is a risk factor for TA-GvHD and supports the proposal that the guidelines for prophylactic irradiation of cellular blood products be extended to include all cases of NHL.
Asunto(s)
Transfusión de Eritrocitos/efectos adversos , Enfermedad Injerto contra Huésped/etiología , Macroglobulinemia de Waldenström/complicaciones , Anciano , Incompatibilidad de Grupos Sanguíneos , Tipificación y Pruebas Cruzadas Sanguíneas , Enfermedad Injerto contra Huésped/diagnóstico , Humanos , Leucemia Linfocítica Crónica de Células B , Masculino , Esterilización , Macroglobulinemia de Waldenström/terapiaAsunto(s)
Linfoma de Células del Manto/complicaciones , Linfoma de Células del Manto/microbiología , Adulto , Antígenos CD/metabolismo , Femenino , Humanos , Huésped Inmunocomprometido , Linfoma de Células del Manto/clasificación , Linfoma de Células del Manto/terapia , Persona de Mediana Edad , Proteínas de Neoplasias/metabolismoRESUMEN
We report a novel chromosomal translocation (X;5)(q13;q33) in a woman with no history of prior chemotherapy or radiotherapy, found to have essential thrombocythemia. Aberrations in chromosome 5, mostly deletions of 5q, have been described in essential thrombocythemia; however, a t(X;5) translocation has not been reported.
